TNF and inflammatory bowel disease: In addition, Th17 signature cytokines, including IL-17A, IL-17B, IL-17D, and IL-17F, have also shown potential as candidate biomarkers for assessing the efficacy of anti-TNF therapy in patients with IBD [38].